2024 Meeting Materials, Vaccines and Related Biological Products Advisory Committee
September 20, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform.
On September 20, 2024, under Topic I, the committee will meet in open session to discuss considerations related to the use of pertussis Controlled Human Infection Models (CHIMs) in pivotal studies to demonstrate efficacy of pertussis vaccines for the purpose of licensure.
Under Topic II, the committee will meet in open session to hear an overview of the Laboratory of Mucosal Pathogens and Cellular Immunology (LMPCI) research program in the Division of Bacterial, Parasitic, and Allergenic Products, Office of Vaccines Research and Review, and CBER. After the open session, the meeting will be closed to the public for committee deliberations.
June 5, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On June 5, 2024, the Committee will meet in open session to discuss and make recommendations on the selection of strain(s) to be included in the 2024-2025 Formula for COVID-19 vaccines.
Postponed - May 16, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On May 16, 2024, the Committee will meet in open session to discuss and make recommendations on the selection of strain(s) to be included in the 2024-2025 Formula for COVID-19 vaccines.
March 5, 2024
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On March 5, 2024, the committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2024 to 2025 influenza season.